# NCT06111235 (NCT06111235)

> A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06111235
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: CG Oncology, Inc.
- Conditions: Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma
- Interventions: Cretostimogene Grenadenorepvec; n-dodecyl-B-D-maltoside
- Enrollment: 367
- Primary outcome: Recurrence Free Survival (RFS)

## Commentary we found

- YouTube: 6
- Podcasts: 6
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06111235

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06111235", "email": "<work email>"}; the inbox owner confirms by the emailed link.